NERV experienced a massive $294.8M swing from profit to loss while dramatically increasing cash and liabilities, indicating significant dilutive financing amid ongoing regulatory challenges with their lead drug candidate.
The company appears to have raised substantial capital (evidenced by the 285% cash increase and massive liability growth) but at significant cost to shareholders, with equity declining by 448% and net income swinging nearly $295M negative. The regulatory focus has narrowed to roluperidone following an FDA Complete Response Letter, suggesting the company is betting everything on successfully completing an additional Phase 3 trial to address FDA deficiencies.
NERV's financials reflect a major capital raise that came at enormous shareholder cost, with stockholders' equity plummeting 448% to -$140.7M while cash increased 285% to $82.3M. The company reduced R&D spending by 52% and improved operating cash flow by 31%, but the massive $294.8M swing to net loss and 272% increase in total liabilities suggest highly dilutive financing or significant one-time charges. This financial profile indicates a company that secured near-term survival funding but at the expense of existing shareholders, typical of biotech companies facing regulatory setbacks requiring additional costly trials.
Net income declined 20492.7% — review whether driven by operations, interest costs, or non-recurring items.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Cash position surged 285.3% — strong cash generation or capital raise providing significant financial cushion.
Current assets grew 273.2% — improving short-term liquidity or inventory/receivables build.
Liabilities grew 272% — significant increase in debt or obligations, assess impact on financial flexibility.
Asset base grew 163.8% — expansion through organic growth, acquisitions, or capital deployment.
Capex reduced 68.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
R&D spending cut 51.6% — could signal cost discipline or concerning reduction in innovation investment.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Operating cash flow surged 30.9% — exceptional cash generation, highest quality earnings signal.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →